With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Cipla has reported consolidated financial results for the period ended March 31, 2022
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
The partners also aim to expand their work to Latin America for the first time
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
RNA extraction free kit to deliver results in just 45 minutes
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
NWSS works with public health departments across the country to track SARS-CoV-2 levels in wastewater so communities can act quickly to prevent the spread of Covid-19.
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
Subscribe To Our Newsletter & Stay Updated
